The tumor-targeting capability of EVs was conferred by the engineered IL4R-targeting peptide using a membrane phospholipid-based linker, dioleylphosphatidylethanolamine (DOPE), with a biological anchor for a membrane (BAM). This evidence concerns the gene IL4R and neoplasm.